Join BJS Academy
BJS Academy>Randomized clinical ...>Atezolizumab plus be...
Normal View Dyslexic View

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

13 February 2024
Randomized clinical trials HPB
Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC et al, for the IMbrave50 investigators.

Lancet 2023; 402: 1835-1847.plus

In this study that included 668 patients followed for a median of 17.4 months, adjuvant treatment improved recurrence-free survival: hazard ratio 0.72, 95 per cent confidence interval 0.53 to 0.98, P=0.012.

Comment: Among the first to show a benefit from adjuvant treatment with immunotherapy.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct042
Randomized clinical trials
Randomized clinical trials
HPB
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC et al, for the IMbrave50 investigators.
13022024
Lancet 2023; 402: 1835-1847.plus
In this study that included 668 patients followed for a median of 17.4 months, adjuvant treatment improved recurrence-free survival: hazard ratio 0.72, 95 per cent confidence interval 0.53 to 0.98, P=0.012.
Comment: Among the first to show a benefit from adjuvant treatment with immunotherapy.
Published on: 13 February 2024
Article ID: rct042

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Kumar M, Patil NS, Mohapatra N, Sindwani G, Dhingra U, Yadav A et al.
Ann Surg 2024; 279: 932-944.

16 August 2024

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!